Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer a unique opportunity to simultaneously address various comorbid associated conditions and phenotypic presentations of polycystic ovary syndrome (PCOS) as these agents improve insulin sensitivity, reduce cardiovascular disease (CVD) risk, result in weight loss, and improve nonalcoholic fatty liver disease.Areas covered: The authors describe trials conducted during the last 5 years and provide an update on exenatide and liraglutide use in PCOS women. Information from the studies investigating GLP-1 RAs effects on reducing CVD risk in PCOS is also presented.Expert opinion: Exenatide and liraglutide are good options for the treatment of PCOS when used alone or in combination with metformin. Especially strong consideration should be given to GLP-1 RAs when developing treatment strategies for PCOS women who are overweight or obese, glucose intolerant, have CVD or its attendant risk factors, and/or are seeking treatment for infertility.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the last years, several studies demonstrated safety and efficacy of exenatide and liraglutide use, alone or in combinations with metformin, in PCOS women [56].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [56]
In the citing paper
“The GLP-1RAs also have positive effects in patients with PCOS decreasing IR and improving metabolic alterations [80,81,82,83].”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [81]
Citations
Cites
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity
Wolf, W. M., Wattick, R. A., Kinkade, O. N., & Olfert, M. D. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15112589 · Cited by 413
Effects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Paschou, S. A., Polyzos, S. A., Anagnostis, P., Goulis, D. G., Kanaka-Gantenbein, C., Lambrinoudaki, I., Georgopoulos, N. A., & Vryonidou, A. (2020) · Endocrine · doi:10.1007/s12020-019-02085-7 · Cited by 231
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223
Salamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0175 · Cited by 204
Research works printed but not linked: 11
- Williams T, 2016, Am Fam Physician, 94
- Hoeger KM, 2020, J Clin Endocrinol Metab, 105
- 10.1900/RDS.2014.11.202 · doi:10.1900/rds.2014.11.202
- Oliver-Williams C, 2020, Eur J Prev Cardiol
- Barber TM, 2021, Clin Endocrinol (Oxf)
- Zheng S, 2017, Obes Med, 7
- Jensterle M, 2015, Hormones
- Lyu X, 2021, Int J Endocrinol [Internet], 1
- Lai Y, 2016, Sci Rep, 6
- Lim SS, 2019, Cochrane Database Syst Rev, 2019
- Je D, 2007, Circulation, 115, 10
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
“Simultaneously, correct administration of medication is crucial to reduce the occurrence of adverse reactions [164, 165, 167, 168, 218].”
BackgroundArmanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
“In the last years, several studies demonstrated safety and efficacy of exenatide and liraglutide use, alone or in combinations with metformin, in PCOS women [56].”
BackgroundEmerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“Furthermore, liraglutide has shown significant improvements in insulin action, cardiovascular disease (CVD) risk, weight reduction (including waist circumference), and reproductive function, including increased pregnancy rates in overweight or obese PCOS women [87].”
BackgroundMetformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Metadata
- Authors
- Siamashvili, M., & Davis, S. N.
- Affiliations
- University of Maryland, Baltimore (US)
- Corresponding author
- Davis, Stephen N.
- ORCID
- Davis, Stephen N.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2021-05-27
- Volume
- 14
- Issue
- 9
- Pages
- 1081-1089
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W3161120012
- Cited by
- 82
- References
- 40
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 17 · 2023: 19 · 2022: 10 · 2021: 1
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- polycystic ovary syndrome, GLP-1 receptor agonists, exenatide, liraglutide, insulin sensitivity, cardiovascular risk, weight loss, non-alcoholic fatty liver disease, metformin combination therapy, obesity, impaired glucose tolerance, infertility
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Metformin, Polycystic Ovary Syndrome, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. https://app.cochat.ai/papers/10.1080/17512433.2021.1933433
- The paper
- Siamashvili, M., & Davis, S. N. (2021). Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2021.1933433
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.